Core Insights - Xiangda Biotechnology has been recognized in the "Forbes Asia 100 to Watch 2025" list, highlighting its achievements and growth potential in the biotech innovation sector [1][3] Recognition - The "Forbes Asia 100 to Watch" list is known for its rigor and authority, aimed at identifying the most innovative and growth-oriented emerging companies in the Asia-Pacific region. Xiangda's inclusion reflects high international recognition of its technological strength and commercial value [4] Innovation and Technology - Xiangda Biotechnology focuses on cutting-edge biotechnological research and application, utilizing its proprietary PHASiFYTM sample concentration extraction technology and intelligent diagnostic platform. Key advantages include: - Enhanced detection sensitivity by 10-100 times, significantly improving early disease detection rates [5] - User-friendly and cost-optimized testing solutions, making advanced diagnostic technology accessible to a broader population [5] - Coverage of multiple diseases, including infectious diseases and early cancer screening [5] - A comprehensive health management solution throughout the product lifecycle [5] Health Management Services - The company offers an integrated health management service system for users, which includes: - Preventive screening with home testing products for infectious diseases and tumors, allowing users to access clinical-grade testing services at home [6] - Accurate diagnostic support for common cancers, ensuring reliability of results [7] - A personalized health intervention system based on testing data, creating a complete health management loop [7] Future Outlook - Following a recent $34 million Series A financing, Xiangda is accelerating its strategic initiatives, which include: - Deepening technological innovation and developing flagship products based on PHASiFYTM technology - Building an intelligent production system to enhance capacity and quality control - Expanding into Asia-Pacific and European markets to promote global business development - Strengthening collaborations with medical institutions and research organizations to build a comprehensive health ecosystem [7]
以创新定义未来!相达生物科技凭硬核实力入选《福布斯亚洲》2025最具关注企业榜
Jiang Nan Shi Bao·2025-08-29 07:38